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A patient with anaplastic meningioma and lung metastases resistant to conventional treatment underwent
radiopeptide therapy with 177Lu- DOTA-octreotate in our institute. The treatment resulted in significant
improvement in patient’s quality of life and inhibition of tumor progression. This case may eventually help to
establish the value of radiopeptide therapy in patients with this rare condition.
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Background
Meningiomas are generally slow-growing lesions that
arise from intracranial and spinal meninges. They are
usually perceived as benign tumours for which radical
surgery is the treatment of choice [1]. However, they
may occasionally behave aggressively in atypical or
malignant meningiomas, invading the brain and/or
metastasising outside the CNS, which occurs in only
0.01% of all cases [2]. The most common extracranial
location of metastasis is the lung followed by liver,
lymph nodes and bones [3,4]. Meningiomas present
ideal targets for somatostatin receptor scintigraphy
(SRS) with 111In-DTPA-octreotide. However, the value
of the radioreceptor therapy using radiolabeled somatos-
tatin analog 177Lu-DOTA-octreotate is not yet well
established in patients with metastasized or inoperable
meningiomas [5,6]. Here, we present a patient with
metastatic anaplastic meningioma who benefited from
radiopeptide targeting.
Case presentation
A 62 year old female with intracranial anaplastic menin-
gioma was referred to our department for a restaging with
18F-fluorodeoxyglucose (FDG)-PET/CT. The patient suf-
fered from a protrusio bulbi of the left eye and progressive
facial pain. No conventional treatment option could be
offered to the patient, who had undergone multiple surgi-
cal resections and percutaneous radiation before.
The fused PET/CT images (Biograph; Siemens Medi-
cal Solutions Inc) manifested multifocal accumulation in
the left temporal region with local bone infiltration.
Furthermore, they demonstrated multiple pulmonary
metastases in the upper lobe of the left lung (Figure 1).
In view of these findings, including the diagnosis of pul-
monary metastases, the patient was referred for SRS to
evaluate the option of a palliative radiopeptide therapy
with 177Lu- DOTA-octreotate. SRS images showed
strong uptake in the left temporal region as well as in
the upper lobe of the left lung, consistent with the PET/
CT findings (Figure 2). Due to the abundance and high
affinity of somatostatin receptors (sstr), we performed
radiopeptide therapy with 177Lu- DOTA-octreotate
consisting of 3 cycles (cumulative dose: 691 mCi) with-
out any serious side effects (Figure 3). The patient
experienced a dramatic reduction of facial pain assessed
by visual analogue scale (VAS) as well as a significant
improvement in quality of life with a 30% increase in
her performance status using karnofsky scoring 6 weeks
after commencement of the treatment. Disease stabiliza-
tion could also be achieved, according to functional MD
Anderson criteria, evaluated 3 months after termination
of radiopeptide therapy [7]
Discussion
The local recurrence rate of meningioma is determined
by the extent of the resection, histopathological grade
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any medium, provided the original work is properly cited.and biological aggressiveness of the tumor [8,9]. Once a
meningioma recurs, it is more likely to recur again later,
resulting in a poor prognosis of the patient [10]. 18F-
FDG-PET/CT has been commonly used in patients with
primary tumours of central nervous system including
meningioma for tumor grading, determination of the
prognosis and discrimination of tumor recurrence from
radiation necrosis [11,12]. With their high sstr density
and location outside the blood-brain barrier, meningio-
mas also present ideal targets for SRS with 111In-
DTPA-octreotide which is the main imaging technique
for neuro endocrine tuomors (NETs) but may be also
used in other tumors expressing somatostatin receptors
such as neuroblastoma, pheochromocytoma and para-
ganglioma [13-15]. This procedure is used apart from
staging and monitoring the effect of treatment for
selecting patients for peptide receptor radionuclide ther-
apy (PRRT), primarily used in gastroenteropancreatic
Figure 1 Maximal intensity projection visualisation of PET/CT
demonstrating the intracranial meningioma and its pulmonary
metastases.
Figure 2 SPECT/CT images of somatostatin receptor
scintigraphy display avid uptake in the intracranial
meningioma (2a and b) as well as in the pulmonary
metastases (2c and d).
Figure 3 Post-therapeutic 177Lu- DOTA-octreotate images
show radiopeptide accumulation in the tumors (A: anterior
view, B: posterior view).
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is not yet well established in patients with meningiomas
[5]. Our patient experienced a dramatic symptomatic
relief as well as a significant improvement in quality of
life following the PRRT along with inhibition of tumor
progression.
Conclusions
The presented case may help to establish the value of
PRRT in patients with the rare condition of anaplastic
meningioma.
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